Hybridoma technology is a method for producing large quantities of identical antibodies, so-called monoclonal antibodies. ¿How are monoclonal antibodies produced? The traditional mAb production process typically begins with the generation of mAb-producing cells (i.e., hybridomas) by fusing myeloma cells with the desired antibody-producing splenocytes (a splenocyte is a white blood cell residing in the spleen) (i.e., B cells). These B cells are generally derived from animals, usually mice. Following cell fusion, large numbers of clones are screened and selected based on antigen specificity and immunoglobulin class. Once candidate hybridoma cell lines are identified, each “hit” is confirmed. Upon completion, the clones are scaled up where additional downstream bioprocesses occur.